GO:0003920 GMP reductase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0003920 (GMP reductase activity) catalyzes the NADPH-dependent reductive deamination of IMP to GMP, a key step in guanine nucleotide biosynthesis.
• The reaction is IMP + NADP+ + NH4+ = GMP + 2 H+ + NADPH, and it is reversible depending on cellular conditions.
• GMP reductase activity is essential for maintaining balanced purine nucleotide pools, particularly the GTP:ATP ratio.
• Dysregulation of GMP reductase has been linked to cancer, immune dysfunction, and senescence-associated inflammation [2,3,4].
• CRISPR knockout, point mutation, and overexpression models enable precise interrogation of GMP reductase function in disease [2,3,4].
• EDITGENE provides end-to-end CRISPR services to study GMP reductase activity in any cell type.
Description
GMP reductase activity (GO:0003920) is a molecular function that catalyzes the conversion of inosine monophosphate (IMP) to guanosine monophosphate (GMP) using NADPH as a reductant. This reaction is a critical branch point in purine nucleotide metabolism, ensuring the production of guanine nucleotides required for RNA, DNA, and protein synthesis. The enzyme is widely conserved and its activity is tightly regulated to maintain cellular nucleotide homeostasis. Researchers study GMP reductase activity to understand how cells balance purine pools and how this balance is disrupted in diseases such as cancer and immune disorders [2,3,4]. Recent evidence links GMP reductase to innate immune signaling and senescence, highlighting its broader biological significance [2,6].
GMP reductase activity At A Glance
| GO ID | GO:0003920 |
|---|---|
| GO term | GMP reductase activity |
| Ontology | molecular_function |
| Synonym | guanosine 5'-monophosphate oxidoreductase activity; guanosine monophosphate reductase activity; guanylate reductase activity; NADPH:GMP oxidoreductase (deaminating) activity |
| Major function | Catalyzes the NADPH-dependent reductive deamination of IMP to GMP |
| Reaction | IMP + NADP+ + NH4+ = GMP + 2 H+ + NADPH |
| Cofactor | NADPH (reducing agent), NADP+ (oxidized form) |
| Pathway | Purine nucleotide biosynthesis (guanine branch) |
| Subcellular location | Cytoplasm (inferred from enzyme function) |
What Is GO:0003920?
According to the Gene Ontology, GMP reductase activity (GO:0003920) is defined as the catalysis of the reaction: IMP + NADP+ + NH4+ = GMP + 2 H+ + NADPH. In other words, it is the enzyme activity that reduces IMP to GMP while oxidizing NADPH to NADP+ and releasing ammonium. This activity is synonymous with guanosine monophosphate reductase, guanylate reductase, and several other names listed in QuickGO. It belongs to the molecular_function ontology aspect and is involved in de novo guanine nucleotide biosynthesis and salvage pathways.
Why Is GMP reductase activity Important in Cell Biology?
GMP reductase activity is essential for maintaining the cellular pool of guanine nucleotides, which are required for DNA replication, RNA transcription, and protein synthesis. Imbalances in guanine nucleotides can lead to replication stress, genomic instability, and altered immune responses. Recent studies have shown that GMP reductase is involved in senescence-associated inflammation and cancer resistance to therapy [2,3]. Therefore, understanding its regulation and function is critical for developing targeted therapies in oncology and immunology.
• Maintains GTP levels for RNA and DNA synthesis.
• Regulates the GTP:ATP ratio, influencing cell growth and proliferation.
• Linked to innate immune signaling via cGAS-STING pathway [2,3].
• Implicated in senescence and age-associated inflammation [2,6].
• Contributes to resistance to gemcitabine and radiotherapy in cancer [3,4].
• Potential target for anticancer and immunomodulatory drugs [2,4].
• Required for mitochondrial function and energy metabolism.
• Involved in purine salvage disorders and metabolic diseases.
• Modulated by cyclic AMP and cyclic GMP signaling.
• Key enzyme for studying nucleotide metabolism in CRISPR screens.
What Happens During GMP reductase activity?
Substrate Binding and Orientation
In simple terms: The enzyme grabs IMP and NADPH to start the reaction.
GMP reductase binds its substrates, IMP and NADPH, in a specific orientation that facilitates the transfer of hydride from NADPH to the substrate. The binding is highly specific, ensuring that only IMP is reduced and not other purine nucleotides.
Reductive Deamination
In simple terms: The enzyme removes an amino group and adds electrons to convert IMP to GMP.
The catalytic mechanism involves the reductive deamination of IMP, where the C2 carbon of the purine ring is aminated using ammonium, while NADPH provides reducing equivalents. This step is rate-limiting and tightly regulated by cellular energy status.
Product Release and Cofactor Recycling
In simple terms: The enzyme releases GMP and recycles NADP+ for other reactions.
After the reaction, GMP is released into the cytoplasm for nucleotide synthesis, and NADP+ is recycled back to NADPH by cellular reductases. This ensures a continuous supply of GMP for RNA and DNA production.
Key Genes Involved in GO:0003920 GMP reductase activity
The following genes and proteins are directly or indirectly involved in GMP reductase activity and its regulation.
| Gene | Major Role | Research Relevance |
|---|---|---|
| GMPR | Encodes GMP reductase enzyme | Directly catalyzes IMP to GMP conversion |
| GMPR2 | Encodes a second GMP reductase isoform | Tissue-specific regulation of guanine nucleotides |
| IMPDH1 | Inosine monophosphate dehydrogenase | Competes with GMP reductase for IMP |
| IMPDH2 | Inosine monophosphate dehydrogenase | Regulates GTP biosynthesis |
| HPRT1 | Hypoxanthine phosphoribosyltransferase | Salvage pathway for purines |
| PRPS1 | Phosphoribosyl pyrophosphate synthetase | Provides PRPP for purine synthesis |
| ATIC | AICAR transformylase/IMP cyclohydrolase | Final steps of de novo purine synthesis |
| GART | Phosphoribosylglycinamide formyltransferase | Purine biosynthesis |
| PAICS | Phosphoribosylaminoimidazole carboxylase | Purine biosynthesis |
| ADSL | Adenylosuccinate lyase | Purine biosynthesis |
| CTPS1 | CTP synthase 1 | Pyrimidine biosynthesis, balances nucleotides |
| CTPS2 | CTP synthase 2 | Pyrimidine biosynthesis |
| RRM1 | Ribonucleotide reductase subunit M1 | Converts NDPs to dNDPs |
| RRM2 | Ribonucleotide reductase subunit M2 | Regulates dNTP pools |
| TXNRD1 | Thioredoxin reductase 1 | Linked to senescence and innate immunity |
| STING1 | Stimulator of interferon genes | cGAS-STING pathway, affected by GMP reductase [2,3] |
| HSPA12B | Heat shock protein family A member 12B | Protects endothelial cells from senescence |
How Is GMP reductase activity Regulated?
GMP reductase activity is regulated at multiple levels. Transcriptionally, the GMPR gene is induced by cyclic AMP and cyclic GMP signaling. Post-translationally, the enzyme can be phosphorylated, affecting its catalytic efficiency. Metabolically, the activity is feedback-inhibited by high GMP levels and activated by low GTP:ATP ratios. Additionally, the enzyme is sensitive to redox status via NADPH availability.
GMP reductase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| GMPR | Cancer proliferation and therapy resistance | Knockout in HCT116 cells |
| GMPR2 | Senescence-associated inflammation | Overexpression in primary fibroblasts |
| STING1 | Innate immune signaling | Point mutation knock-in in THP-1 cells |
| TXNRD1 | Age-associated inflammation | CRISPR KO in senescent cells |
| HSPA12B | Endothelial senescence | Knock-in of tagged HSPA12B |
Cancer and Therapy Resistance
GMP reductase activity is upregulated in several cancers to support increased guanine nucleotide demand for proliferation. Inhibition of GMP reductase sensitizes cancer cells to gemcitabine and radiotherapy by disrupting nucleotide balance and enhancing cGAS-STING-mediated immune responses [3,4]. Thus, targeting GMP reductase is a potential therapeutic strategy.
Senescence and Age-Associated Inflammation
In senescent cells, GMP reductase activity is linked to the innate immune response through the cGAS-STING pathway. Dysregulation of GMP reductase contributes to age-associated inflammation, and its modulation may alleviate chronic inflammation [2,6].
Metabolic Disorders
Altered GMP reductase activity affects purine homeostasis, which is implicated in metabolic disorders such as gout and Lesch-Nyhan syndrome. However, direct mutations in GMPR are rare, and most effects are secondary to other metabolic defects.
From GMP reductase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does GMPR loss affect cancer cell proliferation? | GMPR knockout in cancer cell lines (e.g., HCT116) |
| How does GMPR mutation affect enzyme kinetics? | Point mutation knock-in of catalytic residues |
| Can GMPR overexpression rescue senescence? | Overexpression of GMPR in senescent fibroblasts |
| What is the role of GMPR in immune signaling? | Knockout in immune cells (e.g., THP-1) |
| Does GMPR interact with STING? | Tagged knock-in of GMPR for co-IP |
| Can GMPR be targeted for therapy? | CRISPR library screening for GMPR synthetic lethality |
How to Study the GMP reductase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| NADPH oxidation assay | Enzymatic activity of GMP reductase | Kinetic studies and inhibitor screening |
| CRISPR knockout screen | Gene essentiality and synthetic lethality | Identify GMPR dependencies in cancer |
| Metabolomics (LC-MS) | Nucleotide pool levels | Assess GTP/GMP ratios |
| RNA-seq | Transcriptional changes | Measure immune gene activation |
| Western blot | Protein expression levels | Validate knockout or overexpression |
| Immunoprecipitation | Protein-protein interactions | Study GMPR-STING interaction |
| Flow cytometry | Cell cycle and apoptosis | Evaluate proliferation defects |
| CRISPR library screening | Genome-wide fitness | Discover novel regulators of GMP reductase |
Enzymatic Activity Assays
GMP reductase activity can be measured spectrophotometrically by monitoring NADPH oxidation at 340 nm. This method is used to determine kinetic parameters and inhibitor efficacy.
CRISPR Knockout Screens
Genome-wide CRISPR knockout screens can identify genes that modulate GMP reductase activity or its downstream effects. Such screens have revealed synthetic lethal interactions with GMPR in cancer.
Metabolomics
Mass spectrometry-based metabolomics quantifies intracellular GTP, GMP, and other nucleotides to assess GMP reductase function. This is critical for understanding metabolic reprogramming in disease.
RNA Sequencing
RNA-seq reveals transcriptional changes upon GMPR manipulation, including activation of interferon-stimulated genes [2,3]. This helps link GMP reductase to immune signaling pathways.
How CRISPR Can Be Used to Study GO:0003920 GMP reductase activity
Knockout
CRISPR knockout of GMPR or GMPR2 eliminates GMP reductase activity, leading to reduced GTP levels and growth defects in cancer cells. This model is used to study the enzyme's role in proliferation and therapy resistance.
Point Mutation
Point mutations in the catalytic site of GMPR (e.g., Cys186) can abolish enzymatic activity, allowing structure-function studies. Such models help distinguish catalytic activity from non-enzymatic functions.
Knock-in
Knock-in of tagged GMPR (e.g., FLAG or GFP) enables localization and interaction studies. This is useful for tracking GMP reductase in live cells and identifying binding partners.
Overexpression
Overexpression of GMPR increases GMP reductase activity and can rescue senescence or enhance nucleotide pools. This model is used to test sufficiency in disease phenotypes.
How EDITGENE Supports GMP reductase activity Research
Researchers studying GMP reductase activity-related genes often need to determine whether a candidate gene is causally involved in nucleotide metabolism, immune signaling, or disease progression. EDITGENE provides precise CRISPR tools to generate knockout, point mutation, knock-in, and overexpression models, enabling rigorous functional validation.
Contact EDITGENE today to design your custom CRISPR model for GMP reductase activity research.
Frequently Asked Questions About GMP reductase activity
What is GMP reductase activity?
GMP reductase activity (GO:0003920) is the enzyme activity that catalyzes the conversion of IMP to GMP using NADPH, as defined by the Gene Ontology.
What genes are involved in GMP reductase activity?
The main genes are GMPR and GMPR2, which encode the enzyme isoforms. Other genes like IMPDH1/2 and HPRT1 influence purine pools.
What is the reaction catalyzed by GMP reductase?
The reaction is IMP + NADP+ + NH4+ = GMP + 2 H+ + NADPH, a reductive deamination.
How is GMP reductase activity regulated?
It is regulated by cyclic AMP/GMP signaling, feedback inhibition by GMP, and NADPH availability [7,8].
What diseases are associated with GMP reductase?
Dysregulation is linked to cancer therapy resistance, senescence-associated inflammation, and metabolic disorders [2,3,4].
How can I study GMP reductase activity in the lab?
Use enzymatic assays, CRISPR knockouts, metabolomics, and RNA-seq. EDITGENE offers custom CRISPR models.
What is the role of GMP reductase in cancer?
It supports increased guanine nucleotide synthesis in proliferating cancer cells and contributes to resistance to gemcitabine and radiotherapy [3,4].
Can GMP reductase be targeted therapeutically?
Yes, inhibitors or CRISPR knockout sensitize cancer cells to chemotherapy, making it a potential target.
What is the difference between GMPR and GMPR2?
GMPR and GMPR2 are two isoforms with different tissue distribution and kinetic properties, but both catalyze the same reaction.
How does GMP reductase affect the immune system?
It modulates the cGAS-STING pathway and interferon responses, influencing senescence and inflammation [2,3].
Conclusion
GMP reductase activity (GO:0003920) is a fundamental enzymatic function in purine metabolism, critical for maintaining guanine nucleotide pools and cellular homeostasis. Its dysregulation is increasingly linked to cancer, immune dysfunction, and aging [2,3,4]. CRISPR-based models are powerful tools to dissect its roles and identify therapeutic opportunities. EDITGENE provides comprehensive services to accelerate research on GMP reductase and related pathways.
References
- 2. Hao X et al.. 2024. TXNRD1 drives the innate immune response in senescent cells with implications for age-associated inflammation.. Nat Aging 4(2):185-197 PMID: 38267705
- 3. Zhu L et al.. 2025. Cholesterol biosynthesis induced by radiotherapy inhibits cGAS-STING activation and contributes to colorectal cancer treatment resistance.. Exp Mol Med 57(5):1089-1105 PMID: 40355720
- 4. Park SY et al.. 2025. Nuclear cGAS mediated replication stress and mitotic catastrophe can overcome gemcitabine resistance.. Cancer Lett 633:218009 PMID: 40912600
- 6. Li T et al.. 2025. HSPA12B Protects Against Age-Related Endothelial Cell Senescence by Regulating STING Degradation.. Aging Cell 24(12):e70260 PMID: 41063400
- 7. Henneberg R et al.. 1985. Rapid modulation of rat hepatocyte HMG-CoA reductase activity by cyclic AMP or cyclic GMP.. Physiol Chem Phys Med NMR 17(1):35-40 PMID: 2994125
- 8. Weber G et al.. 1992. Regulation of GTP biosynthesis.. Adv Enzyme Regul 32:57-69 PMID: 1353938
